Insulin Detemir [Rdna Origin]
Cystic Fibrosis-Related Diabetes
Explore 5 assets in Cystic Fibrosis-Related Diabetes →Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Nationwide Children's Hospital
Modality
protein_peptide
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00639626CT.gov Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cystic Fibrosis-Related Diabetes
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Insulin Detemir [Rdna Origin] (this asset) | Nationwide Children's Hospital | P2/3 | CCC · 55 |
| Glargine Insulin | University of Minnesota | P3 | BB |
| Semaglutide | University of Minnesota | P2/3 | B |
| Empagliflozin | University of Minnesota | P2/3 | B |
| Metformin | University of Kansas Medical Center | P2 | CCC |
| Glucose, Anhydrous | Children's Hospital of Philadelphia | Early P1 | CCC |
| Dorzagliatin | University of Pennsylvania | P1 | CC |
| Repaglinide | Arbelaez, Ana Maria | N/A | D |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Insulin Detemir [Rdna Origin] in Cystic Fibrosis-Related Diabetes. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/insulin-detemir-rdna-origin-cystic-fibrosis-related-diabetes
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →